Long-Term Follow-Up of Crohn Disease Fistulas After Local Injections of Bone Marrow-Derived Mesenchymal Stem Cells
Long-Term Follow-Up of Crohn Disease Fistulas After Local Injections of Bone Marrow-Derived Mesenchymal Stem Cells
复制标题
DOI：
10.1016/j.mayocp.2015.03.023
复制
发表时间：
2015-06-01
影响因子：
8.9
通讯作者：
Corazza, Gino Roberto
中科院分区：
文献类型：
--
作者：
Ciccocioppo, Rachele;Gallia, Alessandra;Corazza, Gino Roberto
目的：评价难治性克罗恩瘘患者连续静脉注射自体骨髓间充质干细胞（MSCs）的安全性和有效性。患者和方法：从2007年1月10日至2014年6月30日，前瞻性记录局部注射MSCs的10例患者（5例男性，中位年龄37岁）中的8例患者的临床评价、克罗恩病活动性指数（CDAI）计算、治疗管理和不良事件记录，为期72个月。使用Kaplan-Meier方法估计瘘复发和药物或手术治疗的累积概率，而使用Mann-Whitney U检验计算msc前后CDAI值的差异。结果：骨髓间充质干细胞治疗12个月后疾病缓解(P
Objective: To assess the long-term outcome of patients treated with serial intrafistular injections of autologous bone marrow-derived mesenchymal stem cells (MSCs) for refractory Crohn fistulas in terms of safety and efficacy.Patients and Methods: Starting from January 10, 2007, through June 30, 2014, clinical evaluation, calculation of the Crohn disease activity index (CDAI), therapeutic management, and documentation of adverse events in 8 of the 10 patients (5 men; median age, 37 years) who had been injected locally with MSCs were prospectively recorded for 72 months. Cumulative probabilities of fistula recurrence and medical or surgical treatment were estimated using a Kaplan-Meier method, whereas differences among the pre- and post-MSC CDAI values were calculated with the Mann-Whitney U test.Results: Following disease remission observed after 12 months from MSC treatment (P